Kiniksa Pharmaceuticals International, plc
KNSADrugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 2 past
No catalysts found.
How KNSA's past catalysts played out
KPL-387
Pericarditis
mavrilimumab
COVID
Rilonacept
Recurrent Pericarditis
prednisone
Giant Cell Arteritis
KPL-404
Arthritis, Rheumatoid
KPL-914
Recurrent Pericarditis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KPL-387 | Phase 3 | Pericarditis | - | - |
mavrilimumab | Phase 3 | COVID | - | - |
Rilonacept | Phase 3 | Recurrent Pericarditis | - | - |
prednisone | Phase 2 | Giant Cell Arteritis | - | - |
KPL-404 | Phase 2 | Arthritis, Rheumatoid | - | - |
KPL-914 | Phase 2 | Recurrent Pericarditis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Kiniksa Pharmaceuticals International, plc's drug pipeline?→
CatalystAlert tracks 6 drug candidates in Kiniksa Pharmaceuticals International, plc's (KNSA) pipeline across Phase 3, Phase 2. Its lead program is KPL-387 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kiniksa Pharmaceuticals International, plc's next FDA catalyst?→
Kiniksa Pharmaceuticals International, plc's (KNSA) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KNSA biotech catalysts?→
Add KNSA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kiniksa Pharmaceuticals International, plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.